Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our API

HRTX
Heron Therapeutics, Inc.
stock NASDAQ

At Close
Oct 17, 2025 3:59:55 PM EDT
1.29USD-1.145%(-0.02)638,534
0.00Bid   0.00Ask   0.00Spread
Pre-market
Oct 16, 2025 9:02:30 AM EDT
1.37USD+4.580%(+0.06)0
After-hours
Oct 17, 2025 4:00:30 PM EDT
1.29USD-0.386%(0.00)1,167
OverviewOption ChainMax PainOptionsPrice & VolumeSplitsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 25, 2022
10:58AM EST  Heron Therapeutics Option Alert: Jun 17 $10 Calls at the Ask: 3000 @ $1.85 vs 2659 OI; Earnings 2/23 Before Open [est] Ref=$8.47   Benzinga
Dec 9, 2021
09:55PM EST  Mid-Afternoon Market Update: Nasdaq Falls Over 1%; Reata Pharmaceuticals Shares Plummet   Benzinga
09:46PM EST  Heron Therapeutics Announces FDA Approval OF Indication expansion For ZYNRELEF ; ZYNRELEF Now Indicated In Adults For Soft Tissue Or Periarticular Instillation To Produce Postsurgical Analgesia For Up To 72 Hours After Certain Procedures   Benzinga
08:24AM EST  Heron Therapeutics: FDA Approves Expanded Indication For   RTTNews
08:11AM EST  Heron : FDA Approves NDA For ZYNRELEF Extended-release Solution To Significantly Expand Indication   RTTNews
08:01AM EST  Heron Therapeutics Announces FDA Approval of a Significant Indication Expansion   PR Newswire
Nov 18, 2021
07:34AM EST  Heron Therapeutics Submits HTX-019 NDA For Prevention Of Postoperative Nausea And Vomiting To FDA   RTTNews
07:33AM EST  Heron Therapeutics Reports Submission Of HTX-019 New Drug Application For Prevention Of Postoperative Nausea, Vomiting To FDA   Benzinga
07:30AM EST  Heron Therapeutics Announces Submission of HTX-019 NDA for the Prevention of   PR Newswire
Nov 11, 2021
04:05PM EST  Heron Therapeutics to Present at Upcoming Investor Conferences   PR Newswire
Nov 5, 2021
11:26AM EDT  Heron Therapeutics Sponsored Study Titled 'A Multi-surgery Assessment of ZYNRELEF (HTX-011), AMAZE' Posted To ClinicalTrials.gov; Study Is Recruiting   Benzinga
Nov 3, 2021
05:19PM EDT  Heron Therapeutics Sees FY21 Oncology Care Franchise Net Product Sales Of $20M-$22M   Benzinga
05:18PM EDT  Heron Therapeutics Q3 EPS $(0.51) Beats $(0.61) Estimate, Sales $23.23M Miss $25.51M Estimate   Benzinga
04:01PM EDT  Heron Therapeutics Announces Financial Results for the Three and Nine Months   PR Newswire
09:19AM EDT  The Daily Biotech Pulse: Cerus Climbs On Earnings, Horizon CFO To Retire, Teva Prices Upsized Sustainability-Linked Senior Note Offering   Benzinga
09:10AM EDT  Earnings Scheduled For November 3, 2021   Benzinga
Oct 31, 2021
02:24PM EDT  The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline   Benzinga
Oct 28, 2021
08:31AM EDT  Heron Therapeutics to Report Third Quarter 2021 Financial Results on Wednesday,   PR Newswire
Oct 7, 2021
08:24AM EDT  The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results   Benzinga
Oct 6, 2021
07:33AM EDT  The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal   Benzinga
Oct 4, 2021
08:37AM EDT  Heron Therapeutics Files SNDA For Expansion Of ZYNRELEF Indication Statement Based On Outcome Of FDA Type C Meeting   RTTNews
08:32AM EDT  Heron Therapeutics Reports Filing Of Supplemental New Drug Application For Expansion Of ZYNRELEF Indication Statement   Benzinga
08:31AM EDT  Significant Expansion of ZYNRELEF(r) Indication Statement Based on Successful Outcome of FDA Type C Meeting   PR Newswire
Sep 21, 2021
04:05PM EDT  Heron Therapeutics to Present at the 2021 Cantor Virtual Global Healthcare   PR Newswire
10:46AM EDT  Heron Therapeutics's Return On Capital Employed Overview   Benzinga
Aug 20, 2021
07:45AM EDT  The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data   Benzinga
Aug 19, 2021
10:57AM EDT  The Daily Biotech Pulse: Coherus Soars On Lung Cancer Data, Illumina Closes On Grail Buy Without Regulatory Clearance, Adagene Strikes Collaboration With Merck   Benzinga
Aug 18, 2021
07:38AM EDT  The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline   Benzinga
Aug 17, 2021
08:28AM EDT  The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business   Benzinga
Aug 13, 2021
07:43AM EDT  The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO   Benzinga
Aug 10, 2021
07:55AM EDT  The Daily Biotech Pulse: Arcturus Soars On COVID-19 Vaccine Updates, Merck's Keytruda On Track For More Label Expansions, Eliem Debuts   Benzinga
Aug 9, 2021
08:28AM EDT  Heron Therapeutics Q2 EPS $(0.62) Down From $(0.61) YoY, Sales $22.40M Down From $22.67M YoY   Benzinga
08:09AM EDT  Heron Therapeutics Q2 Loss/shr Widens To $0.62 From $0.61 Prior Year   RTTNews
08:01AM EDT  Heron Therapeutics Announces Financial Results for the Three and Six Months   PR Newswire
Aug 5, 2021
08:08AM EDT  The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO   Benzinga
Aug 4, 2021
07:52AM EDT  The Daily Biotech Pulse: Pfizer's Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings   Benzinga
Jul 29, 2021
08:18AM EDT  The Daily Biotech Pulse: Merck's Disappointing Q2, Atreca Falls On Data, FDA Nod For Viatris, Nuvalent, Icosavax IPOs   Benzinga
Jul 28, 2021
04:42PM EDT  Heron Therapeutics Highlights Publication Of Results From HOPE Study Of ZYNRELEF In Journal 'Pain and Therapy'   Benzinga
04:06PM EDT  Prescription Elimination), Showing ZYNRELEF(tm) Minimizes the Need for Opioids in a Real-World Setting, With 95% of Patients Experiencing an Opioid-free Recovery   PR Newswire
07:33AM EDT  The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal   Benzinga
Jul 22, 2021
07:20AM EDT  Heron Therapeutics' Zynrelef Shows Reduction In Post-Op Pain, Opioid Use Compared To Bupivacaine In Old-Aged Patients   Benzinga
Jul 21, 2021
04:10PM EDT  Heron Therapeutics Announces Publication Showing Reduction of Pain and Opioid Use Compared to Bupivacaine in Patients 65 and Older with ZYNRELEF   Benzinga
04:05PM EDT  Heron Therapeutics Announces Publication Showing Reduction of Pain and Opioid   PR Newswire
Jul 20, 2021
08:20AM EDT  The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street   Benzinga
Jul 16, 2021
07:37AM EDT  The Daily Biotech Pulse: Moderna To Join S&P 500 Index, Thumbs Down For FibroGen's Anemia Drug, Corvus Shelves COVID Study   Benzinga
Jul 6, 2021
08:55AM EDT  Heron Therapeutics Inc. (HRTX) said that it has executed a contract for ZYNRELEF with Apexus LLC.   RTTNews
08:41AM EDT  Heron Therapeutics Announces 340B Prime Vendor Contract With Apexus For ZYNRELEF   Benzinga
08:37AM EDT  Heron Therapeutics Reports 340B Prime Vendor Contract With Apexus For ZYNRELEF   RTTNews
08:30AM EDT  Heron Therapeutics Announces 340B Prime Vendor Contract with Apexus for   PR Newswire
Jul 1, 2021
08:55AM EDT  Heron Therapeutics Inc. (HRTX) said that ZYNRELEF is now commercially available at all national wholesalers and the largest specialty distributors in the United States, as the first and only extended-release dual-acting local anesthetic.   RTTNews
08:34AM EDT  Heron Announces U.S. Launch And Availability Of ZYNRELEF For Management Of Postoperative Pain For Up To 72 Hours   RTTNews
08:31AM EDT  Heron Therapeutics Announces U.S. Commercial Launch, Availability Of ZYNRELEF For Management Of Postoperative Pain For Up To 72 Hours   Benzinga
08:30AM EDT  ZYNRELEF(tm) for the Management of Postoperative Pain for up to 72 Hours   PR Newswire
Jun 2, 2021
11:13AM EDT  Heron Therapeutics Publishes Clinical Trial Titled 'HTX-011 in Spinal Surgery' To ClinicalTrials.Gov   Benzinga
May 25, 2021
04:05PM EDT  Heron Therapeutics to Present at the 2021 Jefferies Virtual Investor Conference   PR Newswire
09:03AM EDT  Heron Therapeutics Reports Sale Of $150 Mln Of Senior Unsecured Convertible Promissory Notes In Private Placement   RTTNews
09:03AM EDT  Heron Therapeutics Announces $150 Million Convertible Debt Financing   PR Newswire
May 13, 2021
11:01AM EDT  Heron's Non-Opioid, Post-Operative Pain Drug Approved By FDA: Why This Is Important   Benzinga
08:28AM EDT  Heron Therapeutics' Zynrelef Gets FDA Approval For   RTTNews
08:09AM EDT  Heron Therapeutics Reports FDA Approval Of ZYNRELEF For Management Of Postoperative Pain For Up To 72 Hours   RTTNews
08:01AM EDT  Heron Therapeutics Announces U.S. FDA Approval of ZYNRELEF(tm) (HTX-011) for   PR Newswire
08:01AM EDT  Heron Therapeutics Announce FDA Approval Of ZYNRELEF (HTX-011) For Management Of Postoperative Pain For Up To 72 Hours   Benzinga
May 12, 2021
08:57AM EDT  The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron   Benzinga
May 11, 2021
08:53AM EDT  Benzinga Pro's Top 5 Stocks To Watch For Tuesday, May 11, 2021: GLD, AMC, COIN, HRTX, FLXN   Benzinga
May 10, 2021
01:24PM EDT  Heron Stock Trading Higher After Q1 Earnings, Ahead Of HTX-011 Decision Scheduled This Week   Benzinga
10:16AM EDT  Heron Therapeutics Shares Up 10%; Cantor Fitzgerald Issues Note Titled 'HTX-011 in Labeling Discussions, No Questions Outstanding'   Benzinga
10:10AM EDT  Heron Therapeutics Option Alert: May 21 $18 Calls at the Ask: 1900 @ $3.4 vs 8057 OI; Earnings 5/21 After Close [est] Ref=$18.25   Benzinga
08:44AM EDT  Heron Sees FY21 Net Product Sales For Oncology Care Franchise $130M-$145M   Benzinga
08:43AM EDT  Heron Therapeutics Q1 EPS $(0.58) Down From $(0.57) YoY, Sales $20.00M Down From $25.40M YoY   Benzinga
08:40AM EDT  Heron Therapeutics Q1 Net Loss $52.6 Mln Vs. $51.6 Mln Last Year   RTTNews
08:31AM EDT  Heron Therapeutics Announces Financial Results for the Three Months Ended March   PR Newswire
Feb 24, 2021
08:45AM EST  Heron Therapeutics Q4 EPS $(0.68) Down From $(0.65) YoY, Net Product Sales $20.60M Down From $35.08M YoY   Benzinga
08:36AM EST  Heron Therapeutics Q4 Net Loss $62.3 Mln Or $0.68/shr Vs. Loss $57.9 Mln Or $0.65/shr Prior Year   RTTNews
08:30AM EST  Heron Therapeutics Announces Financial Results for the Three and Twelve Months   PR Newswire
Feb 17, 2021
04:06PM EST  Heron Therapeutics to Present at Several Upcoming Virtual Investor Conferences   PR Newswire
Jan 21, 2021
08:41AM EST  Heron Publishes Results From EPOCH 1 Follow-On Study Of HTX-011 In Patients Undergoing Bunionectomy Surgery   RTTNews
08:39AM EST  Heron Therapeutics Highlights Publication Of Results From EPOCH 1 Follow-On Study Of HTX-001 In Patients With Undergoing Bunionectomy Surgery: '77% of Bunionectomy Patients Receiving HTX-011 Required No Opioids...'   Benzinga
08:31AM EST  Heron Therapeutics Announces Publication of Results from EPOCH 1 Follow-On   PR Newswire
Jan 11, 2021
08:44AM EST  Heron Annouunces Progress In Pain Management And CINV Franchises   RTTNews
08:34AM EST  Heron Therapeutics Highlights Progress In Pain Management And CINV Franchises And Announces New Development Program   Benzinga
08:31AM EST  Heron Therapeutics Highlights Progress in Pain Management and CINV Franchises   PR Newswire
Dec 2, 2020
06:21AM EST  SVB Leerink Maintains Outperform on Heron Therapeutics, Raises Price Target to $24   Benzinga
Nov 13, 2020
08:33AM EST  Heron Therapeutics Resubmits NDA To FDA For HTX-011 For Treatment Of Postoperative Pain   RTTNews
08:31AM EST  Heron Therapeutics Resubmits New Drug Application To FDA For HTX-001 For The Treatment Of Postoperative Pain   Benzinga
08:31AM EST  Heron Therapeutics Resubmits New Drug Application to FDA for HTX-011 for the   PR Newswire
Nov 12, 2020
12:09PM EST  Heron Therapeutics Option Alert: Dec 18 $17 Calls at the Ask: 1300 @ $1.301 vs 155 OI; Ref=$16.9601   Benzinga
Nov 11, 2020
04:05PM EST  Heron Therapeutics to Present at Several Upcoming Virtual Investor Conferences   PR Newswire
Nov 5, 2020
08:44AM EST  Heron Therapeutics Q3 Loss/Shr $0.64 Vs Loss $0.42 Last Year   RTTNews
08:38AM EST  Heron Therapeutics Q3 EPS $(0.64) Down From $(0.42) YoY, Sales $19.96M Down From $42.62M YoY   Benzinga
08:31AM EST  Heron Therapeutics Announces Financial Results for the Three and Nine Months   PR Newswire
Sep 28, 2020
08:36AM EDT  Heron Therapeutics Receives EU Authorization For ZYNRELEF For Postoperative Pain   RTTNews
08:35AM EDT  Heron Therapeutics Receives European Commission Authorization For ZYNRELEF For The Treatment Of Postoperative Pain   Benzinga
08:30AM EDT  Heron Therapeutics Receives European Commission Authorization for ZYNRELEF(tm)   PR Newswire
Sep 16, 2020
08:36AM EDT  Heron Therapeutics Announces Publication Of Results From EPOCH 2 Follow-On Study   RTTNews
08:33AM EDT  Heron Therapeutics Highlights Publication Of Results From EPOCH 2 Follow-On Study, A Phase 2b Study Of HTX-011 In Patients Undergoing Hernia Repair Surgery   Benzinga
08:31AM EDT  Study, a Phase 2b Study of HTX-011 in Patients Undergoing Hernia Repair Surgery   PR Newswire
Sep 11, 2020
04:05PM EDT  Heron Therapeutics to Present at Cantor Virtual Global Healthcare Conference   PR Newswire
Sep 8, 2020
10:14AM EDT  Shares of Heron Therapeutics Inc. (HRTX) are rising over 8% today, after the company announced a successful Type A meeting with the U.S. Food and Drug Administration or FDA in which alignment was reached on the plans for the company to resubmit the New Drug Application or NDA for HTX-011 for the management of postoperative pain in the fourth quarter of this year.   RTTNews
08:51AM EDT  Heron Therapeutics, Inc. (HRTX) announced a successful Type A meeting with the FDA in which alignment was reached on the plans for the company to resubmit the New Drug Application for HTX-011 for the management of postoperative pain in the fourth quarter of current year. The company plans to resubmit the HTX-011 NDA in the next few months.   RTTNews
08:38AM EDT  Heron Reports Successful Outcome Of FDA Type A Meeting To Discuss HTX-011 For Management Of Postoperative Pain; Stock Up   RTTNews
08:32AM EDT  Heron Therapeutics Announces Successful Outcome Of FDA Type A Meeting To Discuss HTX-011 For Management Of Postoperative Pain; Says 'alignment was reached on the plans for the Company to resubmit the New Drug Application' For HTX-011   Benzinga
08:31AM EDT  Heron Therapeutics Announces Successful Outcome of FDA Type A Meeting to   PR Newswire
Aug 5, 2020
04:39PM EDT  Heron Therapeutics Q2 EPS $(0.61) Up From $(0.63) YoY, Sales $22.67M Down From $36.66M YoY   Benzinga
04:05PM EDT  Heron Therapeutics Announces Financial Results for the Three and Six Months   PR Newswire
Jul 24, 2020
08:38AM EDT  Heron Therapeutics Reports Positive CHMP Opinion For ZYNRELEF For Mgmt. Of Postoperative Pain   Benzinga
08:32AM EDT  Heron Therapeutics Gets Positive CHMP Opinion For ZYNRELEF For The Management Of Postoperative Pain   RTTNews
08:31AM EDT  Heron Therapeutics Receives Positive CHMP Opinion for ZYNRELEF(tm) (HTX-011)   PR Newswire
Jul 16, 2020
08:34AM EDT  Heron Therapeutics Announces Initiation Of Phase 2 Clinical Study Of CINVANTI For Treatment Of Coronavirus   Benzinga
08:32AM EDT  Heron Therapeutics Begins GUARDS-1 Study, A Phase 2 Clinical Study Evaluating CINVANTI   RTTNews
08:31AM EDT  Heron Therapeutics Announces Initiation of Phase 2 Clinical Study of   PR Newswire
Jul 14, 2020
12:53PM EDT  Heron Therapeutics Registers New Phase 2 Clinical Trail For Aprepitant Injectable Emulsion In Patients With Coronavirus   Benzinga


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC